002603 以岭药业
交易中 07-23 13:54:39
资讯
新帖
简况
以人类健康为己任，以岭药业荣获证券之星ESG新标杆企业奖
证券之星 · 07-22 14:17
以人类健康为己任，以岭药业荣获证券之星ESG新标杆企业奖
以岭药业最新公告：2023年度权益分派10派3元 股权登记日7月18日
证券之星 · 07-11
以岭药业最新公告：2023年度权益分派10派3元 股权登记日7月18日
以岭药业“苯胺洛芬注射液”新药注册申请获国家药监局正式受理
证券之星 · 07-11
以岭药业“苯胺洛芬注射液”新药注册申请获国家药监局正式受理
以岭药业入选《中国科技创新评价体系研究与实践》科创优秀案例
证券之星 · 07-11
以岭药业入选《中国科技创新评价体系研究与实践》科创优秀案例
以岭药业(002603.SZ)发预减，预计上半年净利润4.34亿元—6.42亿元，同比下降60%—73%
智通财经 · 07-10
以岭药业(002603.SZ)发预减，预计上半年净利润4.34亿元—6.42亿元，同比下降60%—73%
2024中国中药研发实力排行榜发布，以岭药业摘得榜眼
证券之星 · 07-10
2024中国中药研发实力排行榜发布，以岭药业摘得榜眼
以岭药业：预计2024年1-6月归属净利润盈利4.34亿元至6.42亿元
证券之星 · 07-10
以岭药业：预计2024年1-6月归属净利润盈利4.34亿元至6.42亿元
以岭药业最新公告：上半年净利预降60%-73%
证券之星 · 07-10
以岭药业最新公告：上半年净利预降60%-73%
以岭药业（002603）股东吴瑞质押120万股，占总股本0.07%
证券之星 · 07-05
以岭药业（002603）股东吴瑞质押120万股，占总股本0.07%
以岭药业（002603）股东吴相君质押80万股，占总股本0.05%
证券之星 · 06-21
以岭药业（002603）股东吴相君质押80万股，占总股本0.05%
以岭药业：我们会及时反馈至公司管理层及电商部门参考
证券之星 · 06-21
以岭药业：我们会及时反馈至公司管理层及电商部门参考
以岭药业新提交1件商标注册申请
证券之星 · 06-17
以岭药业新提交1件商标注册申请
以岭药业最新公告：“柴黄利胆胶囊”新药注册申请已获正式受理
证券之星 · 06-13
以岭药业最新公告：“柴黄利胆胶囊”新药注册申请已获正式受理
以岭药业(002603.SZ)子公司柴黄利胆胶囊药品注册申请获受理
智通财经 · 06-13
以岭药业(002603.SZ)子公司柴黄利胆胶囊药品注册申请获受理
重磅！以岭药业创新中药治疗早衰研究取得重大突破
证券之星 · 06-05
重磅！以岭药业创新中药治疗早衰研究取得重大突破
以岭药业新注册《以岭药业招标采购平台V1.0》项目的软件著作权
证券之星 · 06-02
以岭药业新注册《以岭药业招标采购平台V1.0》项目的软件著作权
以岭药业泽泻上榜2024年优质药材“三无一全”基地品种榜单
证券之星 · 05-29
以岭药业泽泻上榜2024年优质药材“三无一全”基地品种榜单
[路演]以岭药业：独特络病理论引领中药创新 研发能力居中药行业前列
证券之星 · 05-22
[路演]以岭药业：独特络病理论引领中药创新 研发能力居中药行业前列
以岭药业（002603）5月16日主力资金净卖出5918.49万元
证券之星 · 05-17
以岭药业（002603）5月16日主力资金净卖出5918.49万元
世界品牌莫干山大会｜以岭药业张蕴龄：创新引领开启大健康产业发展新篇章
证券之星 · 05-14
世界品牌莫干山大会｜以岭药业张蕴龄：创新引领开启大健康产业发展新篇章
公司概况
公司名称：
石家庄以岭药业股份有限公司
所属行业：
医药制造业
上市日期：
2011-07-28
主营业务：
石家庄以岭药业股份有限公司是一家主要致力于专利创新中药的研发、生产和销售。公司拥有通过GMP认证的胶囊、片剂、颗粒剂、针剂生产线,以及通过欧盟认证的化学药制剂车间。
发行价格：
34.56
{"stockData":{"symbol":"002603","market":"SZ","secType":"STK","nameCN":"以岭药业","latestPrice":15.52,"timestamp":1721714079000,"preClose":15.8,"halted":0,"volume":6110400,"delay":0,"floatShares":1377000000,"shares":1671000000,"eps":0.2717,"marketStatus":"交易中","marketStatusCode":2,"change":-0.28,"latestTime":"07-23 13:54:39","open":15.74,"high":15.83,"low":15.46,"amount":95364700,"amplitude":0.0234,"askPrice":15.52,"askSize":130,"bidPrice":15.51,"bidSize":4,"shortable":0,"etf":0,"ttmEps":0.2717,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1721718000000},"adr":0,"adjPreClose":15.8,"symbolType":"stock","openAndCloseTimeList":[[1721698200000,1721705400000],[1721710800000,1721718000000]],"highLimit":17.38,"lowLimit":14.22,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":1670705376,"pbRate":2.25,"roa":"--","roe":"2.62%","epsLYR":0.8095,"committee":0.142857,"marketValue":25929000000,"floatMarketCap":21368000000,"peRate":57.121827,"changeRate":-0.0177,"turnoverRate":0.0044,"status":1},"requestUrl":"/m/hq/s/002603/wiki","defaultTab":"wiki","newsList":[{"id":"2453739784","title":"以人类健康为己任，以岭药业荣获证券之星ESG新标杆企业奖","url":"https://stock-news.laohu8.com/highlight/detail?id=2453739784","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2453739784?lang=zh_cn&edition=full","pubTime":"2024-07-22 14:17","pubTimestamp":1721629065,"startTime":"0","endTime":"0","summary":"为表彰经济效能与社会责任并重的绿色企业，为中国ESG发展提供示范性样本，助力上市公司引领绿色发展，履行社会责任，提升公司治理水平，助推经济可持续、高质量发展，本届ESG研讨会证券之星联合华证指数发布了2024年《ESG投资价值TOP100榜单》，并颁发证券之星ESG新标杆企业奖。以岭药业入选ESG投资价值TOP100榜单并荣获证券之星ESG新标杆企业奖。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2024072200012666.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","002603","BK0042","BK0097","159717","BK0239","BK0046","161027"],"gpt_icon":0},{"id":"2450354672","title":"以岭药业最新公告：2023年度权益分派10派3元 股权登记日7月18日","url":"https://stock-news.laohu8.com/highlight/detail?id=2450354672","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450354672?lang=zh_cn&edition=full","pubTime":"2024-07-11 20:30","pubTimestamp":1720701040,"startTime":"0","endTime":"0","summary":"以岭药业公布2023年年度权益分派实施公告，公司2023年年度权益分派方案为：向全体股东每10股派3元人民币现金(含税)。本次权益分派股权登记日为：2024年7月18日，除权除息日为：2024年7月19日。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071100040345.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002603","BK0042","BK0239","BK0097","BK0188","BK0046"],"gpt_icon":0},{"id":"2450805990","title":"以岭药业“苯胺洛芬注射液”新药注册申请获国家药监局正式受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2450805990","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450805990?lang=zh_cn&edition=full","pubTime":"2024-07-11 11:25","pubTimestamp":1720668322,"startTime":"0","endTime":"0","summary":"7月10日晚，以岭药业发布公告称，收到国家药品监督管理局下发的《受理通知书》，公司提交的“苯胺洛芬注射液”新药注册申请已获正式受理。苯胺洛芬注射液是以岭药业自主研发的化学药新药，从化学结构上属于芳基烷酸类镇痛抗炎药，为非甾体类镇痛药，可以抑制前列腺素合成，通过阻断炎症介质发挥镇痛抗炎作用，拟用于成人手术后轻至中度疼痛，与阿片类镇痛药联合用于治疗术后中至重度疼痛。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2024071100020393.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0042","BK0046","BK0097","BK0188","002603"],"gpt_icon":0},{"id":"2450875847","title":"以岭药业入选《中国科技创新评价体系研究与实践》科创优秀案例","url":"https://stock-news.laohu8.com/highlight/detail?id=2450875847","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450875847?lang=zh_cn&edition=full","pubTime":"2024-07-11 08:37","pubTimestamp":1720658248,"startTime":"0","endTime":"0","summary":"会上，《中国科技创新评价体系研究与实践》正式发布，以岭药业入选科创优秀案例。会上发布的《中国科技创新评价体系研究与实践》主要包含上市公司科创能力评价体系及指数报告、科创领军者成长五年调研报告和科创优秀案例三部分内容，其研究成果为我国科技创新评价体系的完善提供了有力的理论支撑和实践指导。以岭药业创新药立足国内，布局国际。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2024071100012281.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0097","BK0188","002603","159982","BK0042","BK0239","BK0046"],"gpt_icon":0},{"id":"2450924848","title":"以岭药业(002603.SZ)发预减，预计上半年净利润4.34亿元—6.42亿元，同比下降60%—73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2450924848","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450924848?lang=zh_cn&edition=full","pubTime":"2024-07-10 20:58","pubTimestamp":1720616295,"startTime":"0","endTime":"0","summary":"智通财经APP讯，以岭药业(002603.SZ)发布2024年半年度业绩预告，公司预计上半年归属于上市公司股东的净利润4.34亿元—6.42亿元，同比下降60%—73%;扣除非经常性损4.16亿元—6.16亿元，同比下降60%—73%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1148990.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["002603"],"gpt_icon":0},{"id":"2450913348","title":"2024中国中药研发实力排行榜发布，以岭药业摘得榜眼","url":"https://stock-news.laohu8.com/highlight/detail?id=2450913348","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450913348?lang=zh_cn&edition=full","pubTime":"2024-07-10 20:20","pubTimestamp":1720614055,"startTime":"0","endTime":"0","summary":"会上，备受瞩目的“2024中国中药研发实力排行榜TOP50”正式揭晓，以岭药业位列2024中国中药研发实力排行榜第二名。据悉，中国中药研发实力排行榜为第九届发布，以岭药业连续九年登上该榜单。2023年，以岭药业在研发方面加大投入至9.35亿，占公司总收入比例超过9%，处于同行业领先水平。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2024071000043820.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK1515","BK1191","BK0042","BK0239","002603","BK0188","BK1606","BK0097","00570"],"gpt_icon":0},{"id":"2450998538","title":"以岭药业：预计2024年1-6月归属净利润盈利4.34亿元至6.42亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2450998538","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450998538?lang=zh_cn&edition=full","pubTime":"2024-07-10 20:02","pubTimestamp":1720612940,"startTime":"0","endTime":"0","summary":"证券之星消息，以岭药业发布业绩预告，预计2024年1-6月归属净利润盈利4.34亿元至6.42亿元。公告中解释本次业绩变动的原因为：主要是公司呼吸类产品受到去年同期高基数及社会库存高企导致的市场需求下降等因素影响所致。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071000042502.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["002603"],"gpt_icon":0},{"id":"2450966388","title":"以岭药业最新公告：上半年净利预降60%-73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2450966388","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2450966388?lang=zh_cn&edition=full","pubTime":"2024-07-10 19:51","pubTimestamp":1720612270,"startTime":"0","endTime":"0","summary":"以岭药业公告，预计2024年半年度归属于上市公司股东的净利润4.34亿元-6.42亿元，同比下降60%-73%。主要是公司呼吸类产品受到去年同期高基数及社会库存高企导致的市场需求下降等因素影响所致。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024071000041843.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","002603","BK0042","BK0188","BK0097"],"gpt_icon":0},{"id":"2449260336","title":"以岭药业（002603）股东吴瑞质押120万股，占总股本0.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2449260336","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2449260336?lang=zh_cn&edition=full","pubTime":"2024-07-05 21:27","pubTimestamp":1720186070,"startTime":"0","endTime":"0","summary":"证券之星消息，以岭药业7月5日公开信息显示，股东吴瑞向广发证券股份有限公司合计质押120.0万股，占总股本0.07%。质押详情见下表：截止本公告日，股东以岭医药科技有限公司已累计质押股份4900.0万股，占其持股总数的9.3%，股东吴相君已累计质押股份1216.0万股，占其持股总数的3.5%，股东吴瑞已累计质押股份846.0万股，占其持股总数的21.64%。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024070500048036.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0046","002603","BK0042","BK0188","BK0097"],"gpt_icon":0},{"id":"2445757280","title":"以岭药业（002603）股东吴相君质押80万股，占总股本0.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2445757280","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445757280?lang=zh_cn&edition=full","pubTime":"2024-06-21 21:25","pubTimestamp":1718976325,"startTime":"0","endTime":"0","summary":"证券之星消息，以岭药业6月21日公开信息显示，股东吴相君向中信证券股份有限公司合计质押80.0万股，占总股本0.05%。质押详情见下表：截止本公告日，股东以岭医药科技有限公司已累计质押股份4900.0万股，占其持股总数的9.3%，股东吴相君已累计质押股份1216.0万股，占其持股总数的3.5%，股东吴瑞已累计质押股份726.0万股，占其持股总数的18.57%。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062100051020.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","002603","BK0042","BK0097","BK0239","BK0046"],"gpt_icon":0},{"id":"2445758725","title":"以岭药业：我们会及时反馈至公司管理层及电商部门参考","url":"https://stock-news.laohu8.com/highlight/detail?id=2445758725","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2445758725?lang=zh_cn&edition=full","pubTime":"2024-06-21 19:01","pubTimestamp":1718967719,"startTime":"0","endTime":"0","summary":"动物实验是评估药物疗效和安全性的重要环节，为临床试验提","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024062100043779.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","BK0097","BK0239","BK0188","BK0046","002603"],"gpt_icon":0},{"id":"2444136927","title":"以岭药业新提交1件商标注册申请","url":"https://stock-news.laohu8.com/highlight/detail?id=2444136927","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2444136927?lang=zh_cn&edition=full","pubTime":"2024-06-17 13:56","pubTimestamp":1718603788,"startTime":"0","endTime":"0","summary":"证券之星消息，根据企查查数据显示，近日石家庄以岭药业股份有限公司新提交1件商标注册申请。商标申请详情如下：今年以来石家庄以岭药业股份有限公司新申请注册商标30件，截止目前公司共持有注册商标1140件，另有187件商标尚在注册申请中。数据来源：企查查以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024061700010800.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0042","BK0097","BK0239","BK0188","BK0046","002603"],"gpt_icon":0},{"id":"2443505274","title":"以岭药业最新公告：“柴黄利胆胶囊”新药注册申请已获正式受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2443505274","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2443505274?lang=zh_cn&edition=full","pubTime":"2024-06-13 18:31","pubTimestamp":1718274668,"startTime":"0","endTime":"0","summary":"以岭药业公告，公司全资子公司北京以岭药业有限公司近日收到国家药品监督管理局下发的《受理通知书》，由北京以岭提交的“柴黄利胆胶囊”新药注册申请已获正式受理。以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024061300034668.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","002603","BK0042","BK0097","BK0239","BK0046"],"gpt_icon":0},{"id":"2443032265","title":"以岭药业(002603.SZ)子公司柴黄利胆胶囊药品注册申请获受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2443032265","media":"智通财经","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2443032265?lang=zh_cn&edition=full","pubTime":"2024-06-13 18:21","pubTimestamp":1718274061,"startTime":"0","endTime":"0","summary":"智通财经APP讯，以岭药业(002603.SZ)发布公告，近日，公司全资子公司北京以岭药业有限公司(简称“北京以岭”)收到国家药品监督管理局下发的《受理通知书》，由北京以岭提交的“柴黄利胆胶囊”新药注册申请已获正式受理。柴黄利胆胶囊是公司自主研制的中药创新药，其功能主治为：清热利湿，疏肝利胆，和胃止痛。用于慢性胆囊炎肝胆湿热、胃失和降证，症见右上腹胀痛或不适，晨起口苦，口干咽干，脘腹胀满，或伴有恶心欲吐，厌食油腻，纳呆，嗳气，身重困倦，烦躁易怒，胸闷不舒，小便黄赤，大便不爽或秘结，舌质红，苔黄腻，脉弦滑数。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1134918.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","BK0042","BK0046","BK0097","BK0188","002603"],"gpt_icon":0},{"id":"2441218599","title":"重磅！以岭药业创新中药治疗早衰研究取得重大突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2441218599","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2441218599?lang=zh_cn&edition=full","pubTime":"2024-06-05 11:20","pubTimestamp":1717557629,"startTime":"0","endTime":"0","summary":"“八子补肾胶囊治疗早衰的随机、双盲、多中心、安慰剂对照临床研究”论文在《植物医学》的发表，阐释了中医药抗衰老的优势，为以岭药业创新中药八子补肾胶囊作为治疗早衰症状的药物提供了临床证据，为医学界治疗早衰研究开辟了新思路！","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2024060500021944.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0046","BK0042","BK0239","BK0188","002603","BK0097"],"gpt_icon":0},{"id":"2440151894","title":"以岭药业新注册《以岭药业招标采购平台V1.0》项目的软件著作权","url":"https://stock-news.laohu8.com/highlight/detail?id=2440151894","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2440151894?lang=zh_cn&edition=full","pubTime":"2024-06-02 01:02","pubTimestamp":1717261326,"startTime":"0","endTime":"0","summary":"证券之星消息，近日以岭药业（002603）新注册了《以岭药业招标采购平台V1.0》项目的软件著作权。今年以来以岭药业新注册软件著作权1个。结合公司2023年年报财务数据，2023年公司在研发方面投入了8.53亿元，同比减17.33%。数据来源：企查查以上内容由证券之星根据公开信息整理，由算法生成（网信算备310104345710301240019号），与本站立场无关，如数据存在问题请联系我们。本文为数据整理，不对您构成任何投资建议，投资有风险，请谨慎决策。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024060200000072.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0097","BK0239","002603","BK0042","BK0046","BK0188"],"gpt_icon":0},{"id":"2439566167","title":"以岭药业泽泻上榜2024年优质药材“三无一全”基地品种榜单","url":"https://stock-news.laohu8.com/highlight/detail?id=2439566167","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2439566167?lang=zh_cn&edition=full","pubTime":"2024-05-29 10:43","pubTimestamp":1716950629,"startTime":"0","endTime":"0","summary":"会上发布了2024年优质药材“三无一全”基地品种，以岭药业泽泻上榜。以岭药业泽泻上榜2024年优质药材“三无一全”基地品种榜单中药材基地共建共享交流大会是由国医大师、中国工程院院士张伯礼等专家以及各知名中药企业共同发起的“国家中药材标准化与质量评估创新联盟”主办的行业交流盛会。自2013年以来，中药材基地共建共享交流大会已举办十届。该基地所产药材全部用于中药芪苈强心胶囊的生产。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2024052900019564.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0097","002603","BK0042","BK0046","BK0188"],"gpt_icon":0},{"id":"2437094364","title":"[路演]以岭药业：独特络病理论引领中药创新 研发能力居中药行业前列","url":"https://stock-news.laohu8.com/highlight/detail?id=2437094364","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2437094364?lang=zh_cn&edition=full","pubTime":"2024-05-22 09:05","pubTimestamp":1716339904,"startTime":"0","endTime":"0","summary":"交流会上，问及研发成果，以岭药业董事长兼总经理吴相君表示，公司形成了独具优势的以络病理论指导临床重大疾病治疗研究，络病理论创新带动专利新药研发的科技核心竞争力，遵循“以临床实践为基础，以理论假说为指导，以治疗方药为依托，以临床疗效为标准”的创新中药研发模式，开展复方中药、组分中药、单体中药多渠道研发，建立了具有自主知识产权的新药研发体系，科技创新能力居中药行业前列。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2024052200013670.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","002603","BK0188","BK0042","BK0097","BK0046"],"gpt_icon":0},{"id":"2436376519","title":"以岭药业（002603）5月16日主力资金净卖出5918.49万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2436376519","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2436376519?lang=zh_cn&edition=full","pubTime":"2024-05-17 09:21","pubTimestamp":1715908892,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2024年5月16日收盘，以岭药业报收于19.49元，下跌1.76%，换手率1.36%，成交量18.75万手，成交额3.69亿元。近5日资金流向一览见下表：以岭药业融资融券信息显示，融资方面，当日融资买入2787.47万元，融资偿还2584.69万元，融资净买入202.78万元，连续3日净买入累计1014.23万元。以岭药业主营业务：专利创新中药的研发、生产和销售。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2024051700015519.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK0188","BK0097","BK0042","002603","BK0046"],"gpt_icon":0},{"id":"2435119591","title":"世界品牌莫干山大会｜以岭药业张蕴龄：创新引领开启大健康产业发展新篇章","url":"https://stock-news.laohu8.com/highlight/detail?id=2435119591","media":"证券之星","labels":[],"top":-1,"share":"https://www.laohu8.com/m/news/2435119591?lang=zh_cn&edition=full","pubTime":"2024-05-14 19:11","pubTimestamp":1715685117,"startTime":"0","endTime":"0","summary":"在5月10日的2024世界品牌莫干山大会系列分论坛——品牌信用建设论坛上，以岭药业报送的《继承创新、造福人类——以岭药业践行ESG理念 打通中医药可持续、高质量发展“经络”》案例入选“大健康领域品牌信用建设典型案例”。在大会“新质健康 慧鉴未来”健康中国品牌发展论坛，以岭药业董事、副总经理张蕴龄作题为《创新引领开启中医药发展新篇章》的主旨发言。以岭药业在微血管病变防治重大慢病研究中取得系列科研成果。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"isJumpTheme":false,"source_url":"https://stock.stockstar.com/SS2024051400028665.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0188","002603","BK0239","BK0046","BK0042","BK0097"],"gpt_icon":0}],"profile":{"ret":0,"listingDate":"2011-07-28","address":"河北省石家庄市裕华区高新技术产业开发区天山大街238号","stockEarnings":[{"period":"1week","weight":0.0276},{"period":"1month","weight":-0.0024},{"period":"3month","weight":-0.1687},{"period":"6month","weight":-0.2644},{"period":"1year","weight":-0.3346},{"period":"ytd","weight":-0.3021}],"companyName":"石家庄以岭药业股份有限公司","boardCode":"AI0027","perCapita":"7027股","boardName":"医药制造业","registeredCapital":"167070万元","compareEarnings":[{"period":"1week","weight":-0.0033},{"period":"1month","weight":-0.0113},{"period":"3month","weight":-0.0191},{"period":"6month","weight":0.0509},{"period":"1year","weight":-0.0642},{"period":"ytd","weight":-0.0036}],"survey":" 石家庄以岭药业股份有限公司是一家主要致力于专利创新中药的研发、生产和销售。公司拥有通过GMP认证的胶囊、片剂、颗粒剂、针剂生产线,以及通过欧盟认证的化学药制剂车间。","serverTime":1721714081497,"listedPrice":34.56,"stockholders":"195905人(较上一季度减少8.55%)","compareStock":{"symbol":"000001.SH","name":"上证指数"}},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.25.1","shortVersion":"4.25.1","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"以岭药业(002603)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供以岭药业(002603)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"以岭药业,002603,以岭药业股票,以岭药业股票老虎,以岭药业股票老虎国际,以岭药业行情,以岭药业股票行情,以岭药业股价,以岭药业股市,以岭药业股票价格,以岭药业股票交易,以岭药业股票购买,以岭药业股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"以岭药业(002603)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供以岭药业(002603)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}